Tag: intranasal administration

Oxytocin’s Inhibitory Effect on Food Intake is Stronger in Obese than Normal-Weight Men

This 2016 double-blind, placebo-controlled study investigated the effects of intranasal oxytocin (24 IU) on food intake and metabolic parameters in 18 obese and 20 normal-weight men. Oxytocin significantly reduced hunger-driven food intake in the fasted state among obese participants but not in normal-weight individuals. Additionally, oxytocin decreased snack consumption in

Read More »

Oxytocin reduces caloric intake in men

This 2015 randomized, double-blind, placebo-controlled crossover study investigated the effects of a single intranasal dose of oxytocin (24 IU) on caloric intake and metabolic parameters in 25 healthy fasting men. Participants received either oxytocin or placebo before selecting and consuming a breakfast meal. Results demonstrated that oxytocin administration led to

Read More »

Oxytocin Reduces Reward-Driven Food Intake in Humans

This 2013 randomized, placebo-controlled crossover study investigated the effects of intranasal oxytocin (24 IU) on food intake and metabolic parameters in healthy men. Participants received oxytocin or placebo, and their food intake was assessed in both fasted and postprandial states. The study found that oxytocin administration significantly reduced snack consumption,

Read More »

Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction

This randomized controlled trial evaluated the safety, pharmacokinetics, and pharmacodynamics of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction (ED). The study found that PT-141 elicited significant erectile responses at doses greater than 7 mg, with erections occurring approximately 30 minutes post-administration. Pharmacokinetic

Read More »